Enhancing myocardial function with cardiac contractility modulation: potential and challenges
- PMID: 37947013
- PMCID: PMC10804199
- DOI: 10.1002/ehf2.14575
Enhancing myocardial function with cardiac contractility modulation: potential and challenges
Abstract
Cardiac contractility modulation (CCM) offers a novel therapeutic avenue for heart failure patients, particularly those unresponsive to cardiac resynchronization therapy within specific QRS duration ranges. This review elucidates CCM's mechanistic underpinnings, its impact on myocardial function, and utility across patient demographics. However, CCM is limited by insufficient data on mortality and hospitalization rate reductions, as well as the need for specialized device implantation skills. While prevailing research has concentrated on left ventricular effects, a knowledge gap persists for other patient subsets. Future inquiries should address combinatory treatment strategies, extended usage and the impact of atrial fibrillation on device implantation. Such expanded studies could refine therapeutic outcomes and widen the scope of beneficiaries.
Keywords: Cardiac contractility modulation; Cardiac devices; Device implantation; Heart failure.
© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Conflict of interest statement
The authors have nothing to disclose.
Figures
Similar articles
-
Cardiac contractility modulation: first experience in heart failure patients with reduced ejection fraction and permanent atrial fibrillation.Europace. 2014 Aug;16(8):1205-9. doi: 10.1093/europace/euu050. Epub 2014 Apr 4. Europace. 2014. PMID: 24706089
-
Comparison of left ventricular reverse remodeling induced by cardiac contractility modulation and cardiac resynchronization therapy in heart failure patients with different QRS durations.Int J Cardiol. 2013 Aug 10;167(3):889-93. doi: 10.1016/j.ijcard.2012.01.066. Epub 2012 Feb 12. Int J Cardiol. 2013. PMID: 22330007
-
How many patients with heart failure are eligible for cardiac contractility modulation therapy?Int J Clin Pract. 2021 Jan;75(1):e13646. doi: 10.1111/ijcp.13646. Epub 2020 Aug 27. Int J Clin Pract. 2021. PMID: 32757431
-
Cardiac contractility modulation in patients with advanced heart failure.Expert Rev Cardiovasc Ther. 2013 May;11(5):635-45. doi: 10.1586/erc.13.48. Expert Rev Cardiovasc Ther. 2013. PMID: 23621145 Review.
-
Device therapy for patients with atrial fibrillation and heart failure with preserved ejection fraction.Heart Fail Rev. 2024 Mar;29(2):417-430. doi: 10.1007/s10741-023-10366-7. Epub 2023 Nov 8. Heart Fail Rev. 2024. PMID: 37940727 Free PMC article. Review.
Cited by
-
Novel Medical Treatments and Devices for the Management of Heart Failure with Reduced Ejection Fraction.J Cardiovasc Dev Dis. 2024 Apr 19;11(4):125. doi: 10.3390/jcdd11040125. J Cardiovasc Dev Dis. 2024. PMID: 38667743 Free PMC article. Review.
References
-
- Authors/Task Force Members:,McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4‐131. doi:10.1002/ejhf.2333 - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous